ライフサイエンスコーパス: bowel cancer

1 nflammatory drugs have reduced risk of large bowel cancer.

2 d tumors which are now the most common small bowel cancer.

3 se patients continue to have a small risk of bowel cancer.

4 tabolic diseases, including diabetes, and in bowel cancer.

5 adenomas, which are precursors of most large-bowel cancers.

6 se, 23 subsequently died (disseminated large bowel cancer, 12; unrelated causes, 9; related causes, 2

7 was inversely related to incidence of large bowel cancer (adjusted relative risk 0.75 [95% CI 0.59-0

8 nd regeneration, as well as diseases such as bowel cancer and inflammatory bowel disease.

9 hain reaction for gastroesophageal and small bowel cancer, and only MMR-IHC for endometrial cancer.

10 ory bowel disease have an increased risk for bowel cancers, and it has been posited that a field of g

11 Most large bowel cancers are moderately to well-differentiated aden

12 The large majority of bowel cancers are thought to be initiated by a partial l

13 Patients recorded in the National Bowel Cancer Audit who underwent urgent or emergency col

14 n made between celiac disease (CD) and small bowel cancers, but there have been no detailed studies o

15 od supports the theory that FAP and sporadic bowel cancer follow the same genetic pathway and are sep

16 intakes of different PUFAs and distal large bowel cancer in a population-based case-control study of

17 association between NSAIDs and distal large bowel cancer in African Americans and whites, using data

18 f patients who underwent resection for large bowel cancer in Maryland.

19 hose from the same dietary factors for large bowel cancer in this cohort.

20 associated with reduced risk of distal large bowel cancer in whites (multivariable odds ratios = 0.88

21 e was inversely associated with distal large bowel cancer in whites (odds ratio (OR) = 0.60, 95% conf

22 sociated with increased risk of distal large bowel cancer in whites, but not among African Americans

23 The incidence of small bowel cancers is increasing.

24 ly to travel to hospitals with better 2-year bowel cancer mortality outcomes.

25 gent fluoropyrimidine adjuvant therapy after bowel cancer resection include intravenous fluorouracil

26 nd 95% confidence intervals for distal large bowel cancer risk in relation to quartiles of PUFA intak

27 acids was inversely related to distal large bowel cancer risk, whereas the ratio of omega-6 to long-

28 s were aged 40 to 69 years, with no previous bowel cancer screening and no family history of CRC.

29 od samples were taken from patients from the Bowel Cancer Screening Programme (asymptomatic but faeca

30 The database used for the NHS Bowel Cancer Screening Programme (BCSP) derives particip

31 The associations between diagnostic pathway (Bowel Cancer Screening Programme (BCSP), IDA, symptomati

32 colorectal polyps is the cornerstone of the Bowel Cancer Screening Programme in the UK.

33 occult blood test as part of the UK national bowel cancer screening programme.

34 ed incidence of colorectal cancer, uptake of bowel cancer screening varies across demographic groups.

35 The highest risks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70 yea

36 The activity of oral UFT in large-bowel cancer when administered with oral LV (approximate

37 ents with polyposis syndromes or other small-bowel cancers, who required small-bowel studies.

38 ents with excluded bowel tumor died of large bowel cancer within 2.4 years; by contrast, the actuaria